阿尔茨海默病,一种代谢障碍:临床进展和基本模型研究 (综述)
Shanhu Zhou1, Limin Tu1, Wei Chen1
1Department of Neurology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, P.R. China.
Experimental and therapeutic medicine
|January 18, 2024
概括
阿尔茨海默病 (AD) 与糖尿病和肥胖等代谢障碍有关. 本综述探讨了它们的并发症和动物模型在研究AD中的作用,为潜在的治疗提供了洞察力.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 代谢性疾病是一种代谢性疾病.
- 伴发病性研究研究.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是认知能力下降,粉样质斑块,神经纤维状结和神经元损失.
- 全球人口老龄化正在经历阿尔茨海默病的发病率上升,造成了重大的健康和经济挑战.
- 流行病学数据表明,阿尔茨海默病与代谢性疾病之间存在联系,这表明有共同的病理途径.
研究的目的:
- 研究阿尔茨海默病与代谢性疾病 (包括糖尿病,肥胖和高胆固醇血症) 的并发症.
- 探索用于代谢性疾病的药物的潜在治疗应用,用于管理AD.
- 审查有关AD病原学的当前研究以及在AD研究中各种动物模型的实用性.
主要方法:
- 对连接AD和代谢性疾病的流行病学证据的文献综述.
- 对阿尔茨海默病与代谢条件之间的病理相似性研究的分析.
- 关于不同动物模型在阿尔茨海默病研究中的作用和局限性的总结.
主要成果:
- 该评论强调了阿尔茨海默病和代谢功能障碍之间的复杂相互作用.
- 证据表明共享的病理机制需要进一步调查.
- 不同的动物模型为研究AD提供了明显的优势,有助于了解疾病进展和测试干预措施.
结论:
- 了解阿尔茨海默病与代谢性疾病的共患性对于开发有效的治疗策略至关重要.
- 代谢疾病药物可能为阿尔茨海默病提供新的治疗途径.
- 适当选择动物模型对于推动AD研究和药物开发至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:15Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:30Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115